# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Benchmark analyst Bill Sutherland reiterates Omnicell (NASDAQ:OMCL) with a Buy and maintains $38 price target.
The table below summarizes Omnicell's second quarter and full year 2024 guidance outlined above. ...
The table below summarizes Omnicell's second quarter and full year 2024 guidance outlined above. ...
Omnicell (NASDAQ:OMCL) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.09) by 1...
Benchmark analyst Bill Sutherland reiterates Omnicell (NASDAQ:OMCL) with a Buy and maintains $38 price target.
Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physicia...
Multi-year Innovation Program Designed to Maximize Value and Outcomes for XT Automated Dispensing SystemOmnicell, Inc. (NASDAQ:...
Benchmark analyst Bill Sutherland maintains Omnicell (NASDAQ:OMCL) with a Buy and lowers the price target from $42 to $38.
Wells Fargo analyst Stan Berenshteyn maintains Omnicell (NASDAQ:OMCL) with a Equal-Weight and lowers the price target from $...